Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serum uric acid and multiple sclerosis.

M Rentzos1, C Nikolaou, M Anagnostouli

  • 1Department of Neurology, Aeginition Hospital-Athens Medical School, 72-74 Vas.Sophias Av, Greece. mrentzos@med.uoa.gr

Clinical Neurology and Neurosurgery
|October 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure.

Access microbiology·2023
Same author

Avoiding appendectomy with an ultrasound probe.

Annals of the Royal College of Surgeons of England·2021
Same author

Combined heart and liver transplantation: an updated systematic review.

Annals of the Royal College of Surgeons of England·2021
Same author

Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients.

Seminars in arthritis and rheumatism·2020
Same author

Heterogeneity of Baló's concentric sclerosis: a study of eight cases with different therapeutic concepts.

BMC neurology·2020
Same author

[The stigma of mental illness: Α historical overview and conceptual approaches].

Psychiatrike = Psychiatriki·2020
Same journal

Clinical response after cerebrospinal fluid shunting in complex versus pure idiopathic normal pressure hydrocephalus: A systematic review and meta-analysis.

Clinical neurology and neurosurgery·2026
Same journal

Preoperative sleep medication use and outcomes following lumbar spine surgery.

Clinical neurology and neurosurgery·2026
Same journal

Long-term real-world outcomes and device management of intrathecal drug delivery systems: A 16-year single-center experience with a primary focus on baclofen therapy.

Clinical neurology and neurosurgery·2026
Same journal

Trends and safety of outpatient versus inpatient lumbar interbody fusion - A national cohort study.

Clinical neurology and neurosurgery·2026
Same journal

A case report on αIN antibody-mediated paraneoplastic cerebellar ataxia.

Clinical neurology and neurosurgery·2026
Same journal

Early prediction of prolonged mechanical ventilation in invasively ventilated patients with subarachnoid hemorrhage: A MIMIC-IV prediction model study.

Clinical neurology and neurosurgery·2026
See all related articles

Multiple sclerosis (MS) patients have lower serum uric acid (UA) levels, a natural scavenger of peroxynitrite (PN). This suggests UA may offer protection against CNS inflammation and warrants further investigation for MS treatment.

Area of Science:

  • Neuroimmunology
  • Biochemistry

Background:

  • Peroxynitrite (PN) is implicated in multiple sclerosis (MS) pathogenesis.
  • Uric acid (UA) is a natural scavenger of PN, and lower serum UA levels have been observed in some MS patients.

Purpose of the Study:

  • To correlate serum UA levels with clinical parameters in MS patients.
  • To investigate changes in serum UA during treatment with immunomodulating or immunosuppressing drugs.

Main Methods:

  • Serum UA levels were measured in 190 MS patients and 58 controls (inflammatory and non-inflammatory diseases).
  • UA levels were correlated with disease type, duration, disability (EDSS), MRI activity, and gender.
  • Serum UA changes were assessed during a 6-month treatment period.

Main Results:

Related Experiment Videos

  • MS patients exhibited significantly lower mean serum UA levels compared to both control groups (p < 0.0001).
  • Serum UA levels did not correlate with disease duration, disability, or MRI activity.
  • Treatment with immunomodulating or immunosuppressing drugs did not influence UA levels (p = 0.85).
  • Patients with Clinically Isolated Syndromes (CIS) also showed significantly lower UA concentrations compared to controls.

Conclusions:

  • Lower serum UA levels in MS may indicate a primary deficiency in protection against nitric oxide-related damage.
  • The development of CNS inflammation in MS may not directly affect serum UA levels.
  • Increasing serum UA levels could be a potential therapeutic strategy for MS.